Noticias de ARGX_US
Noticias del mercado
Últimas noticias sobre ARGX_US — 378 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
/PRNewswire/ -- argenx SE (NASDAQ: ARGX) stock dropped more than 10% in pre-market trading on October 8, 2026, when the Company halted its Phase 3 UNITY study...
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.
The Belgian-Dutch biotech sank after an independent committee halted its pivotal UNITY study for futility, removing a major potential expansion market for Vyvgart.
argenx SE (ARGX) is down 13.8% today. Here is some analysis on what might have caused this price mov
argenx’s experimental CD122 inhibitor met its primary endpoint in a 126-patient study, demonstrating protection against gluten-induced intestinal damage and supporting advancement into late-stage clinical development. Key Investor Takeawaysargenx (NASDAQ:ARGX) reported positive Phase 2 celiac disease trial results for FB102, achieving statistical significance on the primary endpoint (p=0.
At EUR 726.20, Argenx stock was down 12.47 percent on October 8, 2026. The prior close was EUR 829.7
Página 8 de 19